A Prospective Evaluation of Health-Related Quality of Life in Lymphedema Treatment

Saturday, 29 July 2017

Chia Yu Lin, MS
Department of Nursing, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
Hsueh-Erh Liu, PhD, RN
Department of Nursing, College of Nursing, Chang Gung University of Science and Technology, Tao-Yuan, Taiwan


 The vascularized lymph node flap transfer was the flap of choice for lower extremity lymphedema. Although physical rehabilitation is important for lymphedema treatment, there is no standardized procedure for different stage lymphedema. This study was conducted to investigate the vascularized lymph node transfer (VLNT) and Complete Decongestive Therapy (CDT) long term result in lymphedema.


An IRB-approved prospective study was performed of patients who underwent vascularized lymph node transfer for symptomatic upper (ULL) or lower limb (LLL) lymphedema. Patients who had either submental or groin VLN transfer for upper or lower limb lymphedema were isolated. Outcomes were assessed using improvement of circumference reduction, decreased number of episodes of cellulitis and health-related quality of life (HRQOL) metric.


A total 138 patients were identified and met inclusion criteria. More identified patients underwent VLN (50.7%) as compared to CDT (49.3%) for lymphedema. Patient age, BMI, tobacco use, diabetes, hypertension, lymphedema grading and lymphedema reason were similar between groups (p=0.4; p=0.2; p=0.6, p=0.5, p=0.5, p=0.7, p=0.7, respectively). Circumference reduction was higher in the VLN group (35.3%) as compared to the CDT group (23.4%) and post-operative episodes of cellulitis was higher in the CDT group (4 ± 1.5 times per years) as compared to the VLN group (1.4 ± 1.3 times per years) during the 12-month follow-up evaluation, have statistical significance (p=0.03 and p=0.04, respectively). In HRQoL part, overall quality of life and function, body appearance, symptom, and mood domains were all significantly improved in the VNL group(p<0.01 within each domain).


The vascularized lymph node transfer and complete decongestive therapyVLN and are both valuable treatment options in treating lymphedema especially VLN transferred in severe lymphedema (Grade III to IV) was more effective. These improvements are mirrored by improvements in patient-reported outcomes and quality of life measures. These changes can be seen 12 month post-operatively and continued steady improvement can be expected.